![]() S 297995 structure
|
Common Name | S 297995 | ||
---|---|---|---|---|
CAS Number | 916072-89-4 | Molecular Weight | 570.64 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C32H34N4O6 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of S 297995Naldemedine (S-297995) is an orally active, peripherally acting µ-opioid receptor antagonist. Naldemedine shows potent binding affinities (IC50s = 1.15, 1.11, and 1.5 nM, repectively) and antagonist activities (IC50s= 25.57, 7.09, 16.1 nM, repectively) for recombinant human μ-, δ-, and κ- opioid receptors. Naldemedine tempers opioid-induced constipation (OIC) without compromising opioid analgesia[1]. |
Name | Naldemedine |
---|
Description | Naldemedine (S-297995) is an orally active, peripherally acting µ-opioid receptor antagonist. Naldemedine shows potent binding affinities (IC50s = 1.15, 1.11, and 1.5 nM, repectively) and antagonist activities (IC50s= 25.57, 7.09, 16.1 nM, repectively) for recombinant human μ-, δ-, and κ- opioid receptors. Naldemedine tempers opioid-induced constipation (OIC) without compromising opioid analgesia[1]. |
---|---|
Related Catalog | |
In Vivo | Naldemedine (S-297995) (0.001-10 mg/kg; p.o.) significantly represses the opioid-induced inhibition of small intestinal transit in rats. In the subcutaneous Morphine-induced inhibition model, the ED50s ± standard error of the mean is 0.03 ± 0.02 mg/kg for Naldemedine. Subcutaneous morphine-inhibited castor oil-induced diarrhea in rats, and pretreatment with Naldemedine 0.03-1 mg/kg significantly reverses this effect[1]. Animal Model: 6-week-old Crlj: WI male rats[1] Dosage: 0.001-10 mg/kg Administration: P.o. Result: Significantly repressed the opioid-induced inhibition of small intestinal transit in rats by subcutaneous morphine (P < 0.05 or P < 0.01 for naldemedine 0.03-10 mg/kg), and oxycodone (P < 0.01 for naldemedine 0.03-3 mg/kg). |
References |
Molecular Formula | C32H34N4O6 |
---|---|
Molecular Weight | 570.64 |